Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis

Sroczynski G, Schnell-Inderst P, Muehlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, et al. (2011)
European Journal of Cancer 47(11): 1633-1646.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Autor/in
; ; ; ; ; ; ; ; ; ; ;
Alle
Abstract / Bemerkung
Objectives: To systematically evaluate the long-term effectiveness and cost-effectiveness of HPV-based primary cervical cancer screening in the German health care context using a decision-analysis approach. Methods: A Markov-model for HPV-infection and cervical cancer was developed for the German health care context, and applied to evaluate various screening strategies that differ by screening interval and test algorithms, including HPV-testing alone or in combination with cytology. German clinical, epidemiological, and economic data, and test accuracy data from international meta-analyses were used. Outcomes predicted included the reduction in cervical cancer cases and deaths, life expectancy and discounted incremental cost-effectiveness ratios (ICER). The analysis was performed from the perspective of the healthcare system adopting a 3% annual discount rate for costs and outcomes. Extensive sensitivity analyses were performed. Results: HPV-based screening is more effective than cytology alone. It results in a 71-97% reduction in cervical cancer cases as compared to 53-93% for cytology alone. The ICER range from 2600 Euro/LYG (cytology, 5-year-interval) to 155,500 Euro/LYG (annual HPV-testing starting at age 30 years, cytology age 20-29 years). Annual cytology alone, the current recommended screening strategy in Germany, is dominated by HPV-strategies. Increasing the age at screening initiation from 20 to 25 years does not result in a relevant loss in effectiveness but results in lower costs. Conclusions: Based on our analyses, HPV-based cervical cancer screening is more effective than cytology alone and could be cost-effective if performed at intervals of two years or longer. In the German context, an optimal screening strategy may be biennial HPV screening starting at age 30 years preceded by biennial cytology for women aged 25-29 years. Longer screening intervals may be considered in low-risk women with good screening adherence and in populations with low HPV-incidence. (C) 2011 Elsevier Ltd. All rights reserved.
Stichworte
Cost-effectiveness; Cost benefit analyses; Decision analysis; Cervical cancer; Human papillomavirus; Screening
Erscheinungsjahr
2011
Zeitschriftentitel
European Journal of Cancer
Band
47
Ausgabe
11
Seite(n)
1633-1646
ISSN
0959-8049
Page URI
https://pub.uni-bielefeld.de/record/2326711

Zitieren

Sroczynski G, Schnell-Inderst P, Muehlberger N, et al. Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis. European Journal of Cancer. 2011;47(11):1633-1646.
Sroczynski, G., Schnell-Inderst, P., Muehlberger, N., Lang, K., Aidelsburger, P., Wasem, J., Mittendorf, T., et al. (2011). Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis. European Journal of Cancer, 47(11), 1633-1646. doi:10.1016/j.ejca.2011.03.006
Sroczynski, G., Schnell-Inderst, P., Muehlberger, N., Lang, K., Aidelsburger, P., Wasem, J., Mittendorf, T., Engel, J., Hillemanns, P., Petry, K. U., et al. (2011). Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis. European Journal of Cancer 47, 1633-1646.
Sroczynski, G., et al., 2011. Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis. European Journal of Cancer, 47(11), p 1633-1646.
G. Sroczynski, et al., “Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis”, European Journal of Cancer, vol. 47, 2011, pp. 1633-1646.
Sroczynski, G., Schnell-Inderst, P., Muehlberger, N., Lang, K., Aidelsburger, P., Wasem, J., Mittendorf, T., Engel, J., Hillemanns, P., Petry, K.U., Krämer, A., Siebert, U.: Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis. European Journal of Cancer. 47, 1633-1646 (2011).
Sroczynski, G., Schnell-Inderst, P., Muehlberger, N., Lang, K., Aidelsburger, P., Wasem, J., Mittendorf, T., Engel, J., Hillemanns, P., Petry, K. U., Krämer, Alexander, and Siebert, U. “Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis”. European Journal of Cancer 47.11 (2011): 1633-1646.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 21482103
PubMed | Europe PMC

Suchen in

Google Scholar